Quantum Computing: Where Are We Going?
The Pistoia Alliance Quantum Computing Community of Interest is dedicated to exploring the rapidly evolving field of Quantum Computing and its transformative potential for the pharmaceutical industry. While Quantum Computing is still in its developmental stages, the promise it holds for revolutionizing pharma is immense. As stability in Quantum Computing technology is achieved, the opportunities for significant advancements in pharmaceutical research and development will soar.
In the current landscape, AI, ML, and generative AI dominate the spotlight, often overshadowing the advancements in Quantum Computing. This raises several pertinent questions: Does the rise of LLMs diminish the potential benefits of Quantum Computing for pharma? Can some tasks previously envisioned for Quantum Computing be handled by LLMs? How can the pharmaceutical industry integrate Quantum Computing into its problem-solving approaches? Moreover, does the industry possess the necessary skills to embrace this quantum revolution?
To address these crucial questions and more, the Pistoia Alliance is hosting a series of three webinars under the theme “Quantum Computing in Life Science R&D: Where Are We, Where Are We Going, When Will We Get There?”
Agenda
16:00 Welcome
16:05 #1 Pharma – Demand-Side Perspective
Thomas Ehmer, Business Technologies R&D Science and Technology – Innovation Incubator, Merck Group
16:15 #2 Academic Perspective
Brian Marsden, Associate Professor of Data Management and Research Informatics, Director of the NDM Biomedical Platform, Centre for Medicines Discovery & Associate Head of the Medical Sciences Division (Digital & Information)
16:25 #3 Non-Commercial R&D Perspective
Sonali Mohapatra , Quantum Innovation Sector Lead STFC UKRI, NQCC
16:35 Discussion
Chaired by Brian Martin, Head of AI in R&D Information Research, Research Fellow, AbbVie